Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytoDyn has filed a new investigational new drug application for a study to reconfirm dose ranging and to 'prove the principle' with a randomized, double-blind placebo controlled study of Cytolin, the company's drug for treating HIV/AIDS.
Subscribe to our email newsletter
The new study, the first to be sponsored by the drug’s developers, will reconfirm dose ranging and will use the gold standard of the randomized, double-blind, placebo controlled trial to eliminate the need for the industry and public health officials to become familiar with a decade of progress in immunology.
Initially, Cytolin was used experimentally by community physicians to rescue 200 – 300 AIDS patients over a period of two years before the antiretroviral cocktails had become available.
The current need for Cytolin arises because of natural selection, which has caused HIV to mutate to multi-drug resistant strains, the company said.